

**AUGUST 2013 SPECIAL PBAC MEETING OUTCOME – Positive Recommendation**

Drug and Form	Drug use and type	Listing requested by sponsor	PBAC Recommendation
<p><b>Sunitib malate</b> 12.5mg, 25mg and 50mg capsules</p> <p>Sutent®</p>	<p>Pancreatic cancer</p>	<p>Extension of Section 85 Authority Required listing to include initial and continuing treatment of metastatic, unresectable, well-differentiated malignant pancreatic neuroendocrine tumour (or carcinoma) (pancreatic NET) in patients who are symptomatic (despite somatostatin analogues) or who have documented disease progression.</p>	<p>The PBAC recommended listing sunitinib malate as a Section 85 Authority Required listing for unresectable, well-differentiated pancreatic neuroendocrine tumour (pNET) in patients who meet certain criteria.</p> <p>The PBAC considered that in the context of high clinical need, the lack of alternative treatments, the rarity of pNET, the small number of patients predicted and the relatively modest overall financial impact on the PBS, sunitinib was acceptably cost effective for pNET.</p>